AMD3465 HBr
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H406139

CAS#: 185991-07-5 (HBr)

Description: AMD3465, also known as GENZ 644494, is a novel CXCR4 receptor antagonist with potential anticancer and anti-HIV activity. AMD3465 can block infection of T-tropic, CXCR4-using HIV.


Chemical Structure

img
AMD3465 HBr
CAS# 185991-07-5 (HBr)

Theoretical Analysis

Hodoodo Cat#: H406139
Name: AMD3465 HBr
CAS#: 185991-07-5 (HBr)
Chemical Formula: C24H44Br6N6
Exact Mass: 410.32
Molecular Weight: 896.080
Elemental Analysis: C, 32.17; H, 4.95; Br, 53.50; N, 9.38

Price and Availability

Size Price Availability Quantity
5mg USD 300 2 Weeks
10mg USD 550 2 Weeks
25mg USD 950 2 Weeks
Bulk inquiry

Related CAS #: 185991-24-6 (free base)   185991-07-5 (HBr)    

Synonym: AMD3465 HBr, AMD3465 hydrobromide; AMD3465; AMD-3465; AMD 3465; GENZ 644494; GENZ-644494; GENZ644494;

IUPAC/Chemical Name: N-(4-((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzyl)-1-(pyridin-2-yl)methanamine hexahydrobromide

InChi Key: ARHBIBDGWDRBJH-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H38N6.6BrH/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30;;;;;;/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2;6*1H

SMILES Code: [H]Br.[H]Br.[H]Br.[H]Br.[H]Br.[H]Br.C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 896.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang Z, Wu H, Huang S, Chen L, Chen X, Zhang W, Liao L, Zhang X. AMD3465 (hexahydrobromide) rescues the MG63 osteoblasts against the apoptosis induced by high glucose. Biomed Pharmacother. 2021 Jun;138:111476. doi: 10.1016/j.biopha.2021.111476. Epub 2021 Mar 24. PMID: 33773470.


2: Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, Skerlj RT, Bridger GJ, Schols D. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70(5):752-61. doi: 10.1016/j.bcp.2005.05.035. PMID: 16011832.


3: Leung K. 64Cu-{N-[1,4,8,11-Tetraazacyclotetradecanyl-1,4-ph enylenebis(methylene)]-2-(aminomethyl)pyridine}. 2011 Sep 15 [updated 2012 Jan 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22206104.


4: Hu JS, Freeman CM, Stolberg VR, Chiu BC, Bridger GJ, Fricker SP, Lukacs NW, Chensue SW. AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol. 2006 Aug;169(2):424-32. doi: 10.2353/ajpath.2006.051234. PMID: 16877345; PMCID: PMC1599788.


5: Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, Mosi RM, Neff KS, Nelson KL, Ruzek MC, Patel K, Santucci Z, Scarborough R, Wong RS, Bridger GJ, Macfarland RT, Fricker SP. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009 Oct 15;78(8):993-1000. doi: 10.1016/j.bcp.2009.06.010. Epub 2009 Jun 18. PMID: 19540208.


6: Wu D, Jin L, Xu H. The Effects of the CXCR4 Antagonist, AMD3465, on Human Retinal Vascular Endothelial Cells (hRVECs) in a High Glucose Model of Diabetic Retinopathy. Med Sci Monit. 2019 Sep 16;25:6946-6954. doi: 10.12659/MSM.917186. PMID: 31860633; PMCID: PMC6761849.


7: Hartimath SV, Khayum MA, van Waarde A, Dierckx RAJO, de Vries EFJ. N-[11C]Methyl-AMD3465 PET as a Tool for In Vivo Measurement of Chemokine Receptor 4 (CXCR4) Occupancy by Therapeutic Drugs. Mol Imaging Biol. 2017 Aug;19(4):570-577. doi: 10.1007/s11307-016-1028-8. PMID: 27896627; PMCID: PMC5498639.


8: Hartimath SV, van Waarde A, Dierckx RA, de Vries EF. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model. Mol Pharm. 2014 Nov 3;11(11):3810-7. doi: 10.1021/mp500398r. Epub 2014 Aug 18. PMID: 25094028.


9: Hartimath SV, Draghiciu O, Daemen T, Nijman HW, van Waarde A, Dierckx RAJO, de Vries EFJ. Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. Mol Imaging Biol. 2020 Aug;22(4):883-890. doi: 10.1007/s11307-019-01447-x. PMID: 31802362; PMCID: PMC7343732.


10: Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N Jr, Konopleva M, Andreeff M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One. 2013;8(3):e58426. doi: 10.1371/journal.pone.0058426. Epub 2013 Mar 6. PMID: 23484027; PMCID: PMC3590173.


11: De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011 Jun;52(6):986-93. doi: 10.2967/jnumed.110.085613. PMID: 21622896; PMCID: PMC3155288.


12: Zhang X, You L, Chen S, Gao M, Guo Z, Du J, Lu J, Zhang X. Development of a novel 99m Tc-labeled small molecular antagonist for CXCR4 positive tumor imaging. J Labelled Comp Radiopharm. 2018 May 15;61(5):438-446. doi: 10.1002/jlcr.3608. Epub 2018 Feb 27. PMID: 29370457.


13: Zhang T, Yang F, Li W, Liu B, Li W, Chen Z, Wang C. Suppression of the SDF‑1/CXCR4/β‑catenin axis contributes to bladder cancer cell growth inhibition in vitro and in vivo. Oncol Rep. 2018 Sep;40(3):1666-1674. doi: 10.3892/or.2018.6546. Epub 2018 Jul 4. PMID: 30015971.


14: Peng ZH, Xie Y, Wang Y, Li J, Oupický D. Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA. Mol Pharm. 2017 May 1;14(5):1395-1404. doi: 10.1021/acs.molpharmaceut.6b00999. Epub 2017 Jan 30. PMID: 28134535; PMCID: PMC5417087.


15: Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ, Schwartz TW. Molecular mechanism of action of monocyclam versus bicyclam non- peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem. 2007 Sep 14;282(37):27354-27365. doi: 10.1074/jbc.M704739200. Epub 2007 Jun 28. PMID: 17599916.


16: Zhang J, Pang Y, Xie T, Zhu L. CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases. Onco Targets Ther. 2019 Jun 28;12:4985-4992. doi: 10.2147/OTT.S200643. PMID: 31388305; PMCID: PMC6607200.


17: Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. 2012 Aug;14(8):690-701. doi: 10.1593/neo.111810. PMID: 22952422; PMCID: PMC3432475.


18: Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nucl Med Biol. 2014 Aug;41(7):552-61. doi: 10.1016/j.nucmedbio.2014.04.081. Epub 2014 Apr 21. PMID: 25038987; PMCID: PMC4104431.


19: Ghasemi K, Ghasemi K. MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy? Int Immunopharmacol. 2022 Jul;108:108863. doi: 10.1016/j.intimp.2022.108863. Epub 2022 May 25. PMID: 35623288.


20: Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJ, Moore JP. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology. 2007 Aug 1;364(2):431-40. doi: 10.1016/j.virol.2007.03.001. Epub 2007 Apr 10. PMID: 17428517.